Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $22.50, for a total value of $22,500.00. Following the sale, the chief financial officer now owns 23,000 shares in the company, valued at $517,500. The trade was a 4.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Trading Down 3.5 %

Shares of ELVN stock traded down $0.74 during mid-day trading on Wednesday, reaching $20.58. The stock had a trading volume of 260,852 shares, compared to its average volume of 270,231. The stock’s 50-day moving average price is $21.34 and its two-hundred day moving average price is $23.78. The firm has a market capitalization of $1.01 billion, a PE ratio of -10.83 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52-week low of $15.96 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on ELVN shares. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. HC Wainwright raised their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $38.75.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its position in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $97,000. BNP Paribas Financial Markets bought a new position in Enliven Therapeutics in the fourth quarter worth about $112,000. ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics in the fourth quarter worth about $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Enliven Therapeutics in the fourth quarter worth about $228,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.